Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 33, Issue 2, 2013, Pages 58-64

  Wang, Kai Chen ^a,b,c   Lee, Chao Lin ^c   Chen, Shao Yuan ^d,e   Chen, Jeen Chen ^f   Yang, Chih Wen ^c,g   Chen, Shyi Jou ^a,h   Tsai, Ching Piao ^c,g  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e CARDINAL TIEN HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG USE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ADULT; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; SENSITIVITY AND SPECIFICITY;

EID: 84873681781     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0040     Document Type: Article

References (44)

1. Adorini L, Trembleau S. 1997. Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes. Biochem Soc Trans 25(2):625-629. (Pubitemid 27260885)
2. Aktas E, Ciftci F, Bilgic S, Sezer O, Bozkanat E, Deniz O, Citici U, Deniz G. 2009. Peripheral immune response in pulmonary tuberculosis. Scand J Immunol 70(3):300-308.
3. Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pita O, Puddu P. 2002. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 20(4):535-538. (Pubitemid 34846629)
4. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16(4):406-412.
5. Bernard CC, de Rosbo NK. 1991. Immunopathological recognition of autoantigens in multiple sclerosis. Acta Neurol (Na-poli) 13(2):171-178.
6. Caspi RR, Silver PB, Luger D, Tang J, Cortes LM, Pennesi G, Mattapallil MJ, Chan CC. 2008. Mouse models of experimental autoimmune uveitis. Ophthalmic Res 40(3-4):169-174. (Pubitemid 351562898)
7. Chan KH, Ramsden DB, Yu YL, Kwok KH, Chu AC, Ho PW, Kwan JS, Lee R, Lim E, Kung MH, Ho SL. 2009. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol 16(3): 310-316.
8. Cornelio DB, Braga RP, Rosa MW, Ayub AC. 2009. Devic's neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential. Arch Gynecol Obstet 280(3):475-477.
9. Correale J, Fiol M. 2004. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63(12):2363-2370. (Pubitemid 40024351)
10. Cree B. 2008. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 8(5):427-433.
11. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. 2003. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 9(5):521-525. (Pubitemid 37287734)
12. Diehl S, Rincon M. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39(9):531-536. (Pubitemid 35341492)
13. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354(9):942-955.
14. Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W. 2008. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Semin Ophthalmol 23(3):191-200. (Pubitemid 351574422)
15. Horiuchi I, Kawano Y, Yamasaki K, Minohara M, Furue M, Taniwaki T, Miyazaki T, Kira J. 2000. Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J Neurol Sci 172(1):17-24. (Pubitemid 30006976)
16. Hu W, Lucchinetti CF. 2009. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31(4):439-453.
17. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. 1999. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53(8):1692-1697. (Pubitemid 29530341)
18. Li Y, Wang H, Long Y, Lu Z, Hu X. 2011. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 234(1-2):155-160.
19. Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F, Ohyagi Y, Kira J. 2007. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130(Pt 5):1206-1223. (Pubitemid 47355945)
20. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fre-drikson S, Link H. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5(2):101-104. (Pubitemid 29186827)
21. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. 1992. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32(6):758-766.
22. McLaughlin KA, Wucherpfennig KW. 2008. B cells and auto-antibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 98:121-149.
23. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119 (Pt 1):225-237. (Pubitemid 26077567)
24. Nicholson LB, Kuchroo VK. 1996. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 8(6): 837-842. (Pubitemid 27007650)
25. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343(13):938-952.
26. Palace J, Leite MI, Nairne A, Vincent A. 2010. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67(8):1016-1017.
27. Petereit HF, Richter N, Pukrop R, Bamborschke S. 2000. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler 6(1):19-23. (Pubitemid 30175367)
28. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227-231. (Pubitemid 13158528)
29. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. 2007. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 254(9):1233-1237. (Pubitemid 350112363)
30. Sinigaglia F, Sturniolo T, Raddrizzani L, Hammer J. 1997. An-tigenic peptides and autoimmunity. APMIS 105(2):81-88.
31. Tanaka M, Tanaka K, Komori M. 2009. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62(3):167-170.
32. Ubogu EE, Cossoy MB, Ransohoff RM. 2006. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 27(1):48-55. (Pubitemid 43063124)
33. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. 2010. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17(5):672-676.
34. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, Kuwabara S. 2009. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 256(12):2082-2084.
35. Wajgt A, Gorny M. 1983. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies. Acta Neurol Scand 68(5):337-543.
36. Wang HH, Dai YQ, Qiu W, Lu ZQ, Peng FH, Wang YG, Bao J, Li Y, Hu XQ. 2011a. Interleukin-17-secreting T cells in neuro-myelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18(10):1313-1317.
37. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. 2011b. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 18(1):43-46.
38. Warabi Y, Matsumoto Y, Hayashi H. 2007. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252(1):57-61. (Pubitemid 44909191)
39. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y. 2007. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13(1):128-132. (Pubitemid 46152772)
40. Wingerchuk DM. 2006. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res 28(3):348-353. (Pubitemid 43765123)
41. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. 1999. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53(5):1107-1114. (Pubitemid 29442132)
42. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. 2007. The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805-815. (Pubitemid 47238676)
43. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. 2006. Revised diagnostic criteria for neuro-myelitis optica. Neurology 66(10):1485-1489. (Pubitemid 43958540)
44. Wu XM, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Hor-iuchi I, Minohara M, Ohyagi Y, Yamada T, Kira JI. 2000. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci 177(1):24-31.